Genesys Capital

Genesys Capital is a prominent Canadian venture capital firm with over 25 years of experience, focusing on early-stage investments in the life sciences sector. The firm has successfully raised over $400 million across five funds and has been a founding investor in 80% of its portfolio companies. Notable recent exits include Inversago Pharma, acquired by Novo Nordisk for $1.4 billion, and Fusion Pharmaceuticals, acquired by AstraZeneca for $3.3 billion. These successes highlight Genesys' ability to generate fund-level returns driven by local Canadian innovation.

The firm's investment strategy emphasizes co-creating and investing in disruptive Canadian life science opportunities, leveraging its deep scientific network and long-standing partnerships with leading North American research institutes and universities. This approach provides early access to top-tier discoveries and high-potential deal flow, enabling Genesys to build pioneering companies that compete on a global scale.

With a proven team and a consistent company creation investment strategy, Genesys Capital continues to set the standard for life sciences venture capital in Canada, committed to building world-class companies and delivering exceptional returns for its investors.